Avadel Pharmaceuticals (AVDL)
NASDAQ: AVDL
· Real-Time Price · USD
9.00
0.11 (1.24%)
At close: May 16, 2025, 3:59 PM
9.01
0.11%
After-hours: May 16, 2025, 05:10 PM EDT
Avadel Pharmaceuticals Revenue Breakdown
| Period Ending | Dec 31, 2024 |
|---|---|
| Reportable Segment Revenue | 169.12M |
| Reportable Segment Revenue Growth | n/a |
Operating Expense Breakdown
| Period Ending | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 45.58M | 44.62M | 40.39M | 47.41M | 48.62M | 41.3M | 39.16M | 46.78M | 24.47M | 16.98M | 14.1M | 21.8M | 21.64M | 21.03M | 21.28M | 15.17M | 11.01M | 8.97M | 8.42M | 7.09M | 7.91M | 7.66M | 5.32M | 6.76M | 10.45M | 23.2M | 24.83M | 27.84M | 24.49M | 23.06M | 11.56M | 12.43M | 11.81M | 10.69M | 12.74M | 11.29M | 9.46M | 6.81M | 4.57M | 5.87M | 4.46M |
| Selling, General, and Administrative Revenue Growth | +2.15% | +10.46% | -14.79% | -2.50% | +17.73% | +5.47% | -16.29% | +91.18% | +44.09% | +20.47% | -35.35% | +0.78% | +2.90% | -1.21% | +40.26% | +37.80% | +22.71% | +6.54% | +18.72% | -10.34% | +3.26% | +44.15% | -21.34% | -35.31% | -54.97% | -6.56% | -10.82% | +13.71% | +6.20% | +99.41% | -6.97% | +5.22% | +10.52% | -16.11% | +12.84% | +19.33% | +38.97% | +49.04% | -22.22% | +31.59% | n/a |
| Research and Development Revenue | 4.35M | 4.27M | 3.8M | 4.05M | 3.07M | 2.36M | 2.85M | 4.22M | 3.83M | 6.24M | 2.93M | 4.54M | 6.99M | 2.11M | 4.38M | 6.76M | 3.85M | 5.29M | 5.57M | 4.06M | 5.53M | 7.76M | 7.54M | 10.29M | 7.33M | 6.09M | 11.4M | 11.89M | 9.95M | 12.13M | 8.1M | 6.79M | 7.21M | 13.48M | 8.14M | 7.6M | 5.39M | 5.16M | 7.22M | 7.2M | 6.02M |
| Research and Development Revenue Growth | +1.87% | +12.38% | -6.12% | +32.04% | +30.06% | -17.20% | -32.54% | +10.26% | -38.57% | +112.58% | -35.41% | -35.05% | +231.33% | -51.83% | -35.23% | +75.55% | -27.13% | -5.08% | +37.27% | -26.64% | -28.71% | +2.89% | -26.75% | +40.43% | +20.42% | -46.62% | -4.10% | +19.49% | -17.93% | +49.78% | +19.18% | -5.75% | -46.53% | +65.49% | +7.09% | +41.13% | +4.40% | -28.53% | +0.24% | +19.63% | n/a |